Ani Pharmaceuticals Inc. Insider Trading

ANIP

Last 12 months

Insiders sold $15.7M and bought nothing on the open market.

39% of the selling was scheduled in advance under 10b5-1 plans. President & CEO Nikhil Lalwani sold $4.27M on May 11, 14% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2022.

Net open-market

−$15.7M

0 buys · 44 sales

Under a 10b5-1 plan

39%

of the value sold

Insiders who bought / sold

0 / 12

executives and directors

Last open-market buy

Mar 2022

Mar 21, 2022

Get an email when ANIP's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 29	Stephen P. Carey SVP & CFO	Sold10b5-1 plan	2,850	$72.87	208K	1.7%	Form 4
Oct 15	Nikhil Lalwani President & CEO	Sold10b5-1 plan	5,400	$71.89	388K	1.6%	Form 4
Oct 13	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$73.59	37K	0.7%	Form 4
Sep 29	Stephen P. Carey SVP & CFO	Sold10b5-1 plan	2,850	$73.00	208K	1.7%	Form 4
Sep 15	Nikhil Lalwani President & CEO	Sold10b5-1 plan	5,400	$71.00	383K	1.6%	Form 4
Sep 14	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$70.79	35K	0.7%	Form 4
Sep 11	Jeanne Thoma Director	Sold10b5-1 plan	1,000	$71.53	72K	3.6%	Form 4
Aug 31	Stephen P. Carey SVP & CFO	Sold10b5-1 plan	2,850	$72.80	207K	1.6%	Form 4
Aug 25	Nikhil Lalwani President & CEO	Sold10b5-1 plan	5,400	$74.30	401K	1.5%	Form 4
Aug 13	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$75.48	38K	0.7%	Form 4
Aug 10	Ori Gutwerg SVP, Generics	SoldNo plan	3,162	$77.00	243K	4.0%	Form 4
Jul 29	Stephen P. Carey SVP & CFO	Sold10b5-1 plan	2,850	$81.36	232K	1.6%	Form 4
Jul 13	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$81.84	41K	0.6%	Form 4
Jul 2	Stephen P. Carey SVP & CFO	Sold10b5-1 plan	3,313	$86.00	285K	1.8%	Form 4
Jun 29	Stephen P. Carey SVP & CFO	Sold10b5-1 plan	2,850	$84.12	240K	1.6%	Form 4
Jun 12	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$82.03	41K	0.6%	Form 4
Jun 8	Thomas Haughey Director	Sold10b5-1 plan	2,000	$80.88	162K	4.9%	Form 4
Jun 5	Stephen P. Carey SVP & CFO	Sold10b5-1 plan	3,312	$80.00	265K	1.8%	Form 4
May 13	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$78.16	39K	0.6%	Form 4
May 11 – 13	Patrick D Walsh Director	SoldNo plan 2 parts	13,973	$80.66 average	$1.13M	27%	Form 4
May 12	Ori Gutwerg SVP, Generics	SoldNo plan	2,772	$79.50	220K	3.4%	Form 4
May 12	Thomas Andrew Rowland SVP, Head - Established Brands	SoldNo plan	459	$79.21	36K	1.2%	Form 4
May 11	Nikhil Lalwani President & CEO	SoldNo plan	55,000	$77.57	$4.27M	14%	Form 4
Apr 13	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$77.95	39K	0.6%	Form 4
Mar 13	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$72.62	36K	0.6%	Form 4
Mar 13	Christopher Mutz Head of Rare Disease	Sold10b5-1 plan	3,162	$71.64	227K	3.3%	Form 4
Mar 11	Thomas Andrew Rowland SVP, Head - Established Brands	SoldNo plan	4,772	$74.91	357K	11%	Form 4
Mar 6 – 9	Krista Davis SVP, Chief Hr Officer	Sold10b5-1 plan 2 parts	6,572	$74.33 average	488K	11%	Form 4
Mar 6 – 9	Christopher Mutz Head of Rare Disease	Sold10b5-1 plan 2 parts	5,723	$74.19 average	425K	5.7%	Form 4
Mar 5	Stephen P. Carey SVP & CFO	SoldNo plan 2 parts	7,312	$75.50 average	552K	3.8%	Form 4
Mar 3	Ori Gutwerg SVP, Generics	SoldNo plan	2,060	$76.50	158K	2.4%	Form 4
Mar 3	Patrick D Walsh Director	SoldNo plan	6,000	$74.23	445K	10%	Form 4
Mar 2	Christopher Mutz Head of Rare Disease	Sold10b5-1 plan	417	$74.00	31K	0.4%	Form 4
Feb 19 – 20	Krista Davis SVP, Chief Hr Officer	Sold10b5-1 plan 2 parts	3,814	$77.74 average	296K	7.2%	Form 4
Feb 20	Christopher Mutz Head of Rare Disease	Sold10b5-1 plan	5,323	$78.02	415K	5.9%	Form 4
Feb 13	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$76.80	38K	0.7%	Form 4
Feb 12	Christopher Mutz Head of Rare Disease	Sold10b5-1 plan	7,032	$76.55	538K	7.2%	Form 4
Jan 13	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	500	$84.33	42K	0.7%	Form 4
Dec 18, 2025	Krista Davis SVP, Chief Hr Officer	Sold10b5-1 plan	1,622	$82.40	134K	2.7%	Form 4
Dec 12, 2025	Meredith Cook Sr. VP, General Counsel & Sec.	Sold10b5-1 plan	400	$82.32	33K	0.5%	Form 4

Oct 2910b5-1 plan
Stephen P. Carey
SVP & CFO · sold 2,850 at $72.87
208K
1.7% of stake
Oct 1510b5-1 plan
Nikhil Lalwani
President & CEO · sold 5,400 at $71.89
388K
1.6% of stake
Oct 1310b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $73.59
37K
0.7% of stake
Sep 2910b5-1 plan
Stephen P. Carey
SVP & CFO · sold 2,850 at $73.00
208K
1.7% of stake
Sep 1510b5-1 plan
Nikhil Lalwani
President & CEO · sold 5,400 at $71.00
383K
1.6% of stake
Sep 1410b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $70.79
35K
0.7% of stake
Sep 1110b5-1 plan
Jeanne Thoma
Director · sold 1,000 at $71.53
72K
3.6% of stake
Aug 3110b5-1 plan
Stephen P. Carey
SVP & CFO · sold 2,850 at $72.80
207K
1.6% of stake
Aug 2510b5-1 plan
Nikhil Lalwani
President & CEO · sold 5,400 at $74.30
401K
1.5% of stake
Aug 1310b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $75.48
38K
0.7% of stake
Aug 10No plan
Ori Gutwerg
SVP, Generics · sold 3,162 at $77.00
243K
4.0% of stake
Jul 2910b5-1 plan
Stephen P. Carey
SVP & CFO · sold 2,850 at $81.36
232K
1.6% of stake
Jul 1310b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $81.84
41K
0.6% of stake
Jul 210b5-1 plan
Stephen P. Carey
SVP & CFO · sold 3,313 at $86.00
285K
1.8% of stake
Jun 2910b5-1 plan
Stephen P. Carey
SVP & CFO · sold 2,850 at $84.12
240K
1.6% of stake
Jun 1210b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $82.03
41K
0.6% of stake
Jun 810b5-1 plan
Thomas Haughey
Director · sold 2,000 at $80.88
162K
4.9% of stake
Jun 510b5-1 plan
Stephen P. Carey
SVP & CFO · sold 3,312 at $80.00
265K
1.8% of stake
May 1310b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $78.16
39K
0.6% of stake
May 11 – 13No plan
Patrick D Walsh
Director · sold 13,973 at avg $80.66
$1.13M
27% of stake
May 12No plan
Ori Gutwerg
SVP, Generics · sold 2,772 at $79.50
220K
3.4% of stake
May 12No plan
Thomas Andrew Rowland
SVP, Head - Established Brands · sold 459 at $79.21
36K
1.2% of stake
May 11No plan
Nikhil Lalwani
President & CEO · sold 55,000 at $77.57
$4.27M
14% of stake
Apr 1310b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $77.95
39K
0.6% of stake
Mar 1310b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $72.62
36K
0.6% of stake
Mar 1310b5-1 plan
Christopher Mutz
Head of Rare Disease · sold 3,162 at $71.64
227K
3.3% of stake
Mar 11No plan
Thomas Andrew Rowland
SVP, Head - Established Brands · sold 4,772 at $74.91
357K
11% of stake
Mar 6 – 910b5-1 plan
Krista Davis
SVP, Chief Hr Officer · sold 6,572 at avg $74.33
488K
11% of stake
Mar 6 – 910b5-1 plan
Christopher Mutz
Head of Rare Disease · sold 5,723 at avg $74.19
425K
5.7% of stake
Mar 5No plan
Stephen P. Carey
SVP & CFO · sold 7,312 at avg $75.50
552K
3.8% of stake
Mar 3No plan
Ori Gutwerg
SVP, Generics · sold 2,060 at $76.50
158K
2.4% of stake
Mar 3No plan
Patrick D Walsh
Director · sold 6,000 at $74.23
445K
10% of stake
Mar 210b5-1 plan
Christopher Mutz
Head of Rare Disease · sold 417 at $74.00
31K
0.4% of stake
Feb 19 – 2010b5-1 plan
Krista Davis
SVP, Chief Hr Officer · sold 3,814 at avg $77.74
296K
7.2% of stake
Feb 2010b5-1 plan
Christopher Mutz
Head of Rare Disease · sold 5,323 at $78.02
415K
5.9% of stake
Feb 1310b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $76.80
38K
0.7% of stake
Feb 1210b5-1 plan
Christopher Mutz
Head of Rare Disease · sold 7,032 at $76.55
538K
7.2% of stake
Jan 1310b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 500 at $84.33
42K
0.7% of stake
Dec 18, 202510b5-1 plan
Krista Davis
SVP, Chief Hr Officer · sold 1,622 at $82.40
134K
2.7% of stake
Dec 12, 202510b5-1 plan
Meredith Cook
Sr. VP, General Counsel & Sec. · sold 400 at $82.32
33K
0.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ANIP, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ANIP

CompareIntrinsic value

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

PBHPrestige Consumer Healthcare Inc.

$53.28+7.55%48

APLSApellis Pharmaceuticals, Inc.

$3.10+3.29%83

CORTCorcept Therapeutics Incorporated

$77.59-5.30%56

SUPNSupernus Pharmaceuticals Inc.

$28.21+0.21%44

INSMInsmed Inc.

$110.00+5.32%40

Held by ETFs

ANIP is in 76 US ETFs. The largest of them, with ANIP's weight in each:

Spot a number that looks wrong? Check it in ANIP's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ANIP

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.